Clinuvel Financial Statements From 2010 to 2025
| CLVLF Stock | USD 7.91 0.20 2.47% |
Check Clinuvel Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clinuvel Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Clinuvel financial statements analysis is a perfect complement when working with Clinuvel Pharmaceuticals Valuation or Volatility modules.
Clinuvel |
Clinuvel Pharmaceuticals Company Operating Margin Analysis
Clinuvel Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Clinuvel Pharmaceuticals Operating Margin | 0.54 % |
Most of Clinuvel Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clinuvel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Clinuvel Pharmaceuticals has an Operating Margin of 0.5407%. This is 101.54% lower than that of the Healthcare sector and 100.48% lower than that of the Biotechnology industry. The operating margin for all United States stocks is 109.81% lower than that of the firm.
Clinuvel Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Clinuvel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Clinuvel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Clinuvel Pharmaceuticals competition to find correlations between indicators driving Clinuvel Pharmaceuticals's intrinsic value. More Info.Clinuvel Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about 0.95 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Clinuvel Pharmaceuticals is roughly 1.05 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Clinuvel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Clinuvel Pharmaceuticals Financial Statements
Clinuvel Pharmaceuticals stakeholders use historical fundamental indicators, such as Clinuvel Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Clinuvel Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Clinuvel Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Clinuvel Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Clinuvel Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. The company was founded in 1987 and is headquartered in Melbourne, Australia. Clinuvel Pharm operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
Other Information on Investing in Clinuvel Pink Sheet
Clinuvel Pharmaceuticals financial ratios help investors to determine whether Clinuvel Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clinuvel with respect to the benefits of owning Clinuvel Pharmaceuticals security.